Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer
- 381 Downloads
The purpose of this study was to evaluate whether 18F-fluorodeoxyglucose positron emission tomography in combination with computed tomography (FDG-PET/CT) could correctly predict the pathologic response to preoperative chemoradiation therapy (CRT) for resectable pancreatic cancer.
Each of the 40 patients underwent FDG-PET/CT before and after preoperative CRT. The maximum standard uptake value (SUV) was measured for the primary tumor before and after preoperative CRT, defined as pre-CRT SUV and post-CRT SUV, respectively. The proportional alteration of the SUV decline (regression index) between post-CRT SUV and pre-CRT SUV was also calculated. These three indicators were associated with the pathologic response.
Patients were classified as 21 responders and 19 nonresponders according to the histologic features. A pre-CRT SUV ≥4.7 was seen in 15 (71 %) of 21 responders and in 6 (32 %) of 19 nonresponders (p = 0.03). A regression index ≥0.46 was seen in 15 (71 %) responders and 5 (26 %) nonresponders (p = 0.01).
A better pathological response can be expected for pancreatic cancer patients who have a high regression index (≥0.46) and a high pre-CRT SUV (≥4.7). The SUV measurement using FDG-PET/CT is a useful tool for predicting the pathologic response to preoperative CRT.
KeywordsPancreatic Cancer Standard Uptake Value Pathologic Response Regression Index Nonresponder Group
This study was supported in part by a Grant from the Mitsui Life Welfare Foundation and a grant from the Otsuka Research Fund.
Conflict of interest
There are no commercial interests in the subject of this study.
- 20.Sobin L, Gospodarowicz M, Wittekind C (eds) (2010) TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, New YorkGoogle Scholar
- 21.Ohigashi H, Ishikawa O, Eguchi H et al (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250:88–95PubMedCrossRefGoogle Scholar
- 33.Benz MR, Czernin J, Tap WD, et al (2010) FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 143540. Epub Apr 18Google Scholar
- 41.Katz MH, Fleming JB, Bhosale P, et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer doi: 10.1002/cncr.27636. [Epub ahead of print]
- 43.Takahashi H, Ohigashi H, Ishikawa O et al (2012) Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 255:95–102PubMedCrossRefGoogle Scholar